Aktis Oncology (NASDAQ:AKTS – Get Free Report) is projected to issue its Q3 2026 resultson Thursday, November 12th. Analysts expect Aktis Oncology to announce earnings of ($0.47) per share and revenue of $4.02 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The firm had revenue of $3.38 million during the quarter, compared to the consensus estimate of $2.70 million. On average, analysts expect Aktis Oncology to post ($1.84) EPS for the current fiscal year and ($2.45) EPS for the next fiscal year.
Aktis Oncology Stock Performance
Shares of Aktis Oncology stock opened at $15.20 on Thursday. The stock’s 50-day moving average is $19.93 and its 200-day moving average is $20.94. Aktis Oncology has a one year low of $13.96 and a one year high of $34.19.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on AKTS. Wedbush reissued an “outperform” rating and issued a $35.00 target price on shares of Aktis Oncology in a research report on Friday, October 2nd. Oppenheimer assumed coverage on Aktis Oncology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price target for the company. Wall Street Zen downgraded Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Weiss Ratings cut shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 2nd. Finally, BMO Capital Markets began coverage on shares of Aktis Oncology in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.62.
View Our Latest Research Report on Aktis Oncology
About Aktis Oncology
Aktis Oncology, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is directed primarily toward therapies for solid tumors, an area where it seeks to improve the ability of the immune system to recognize and eliminate cancer cells.
Aktis Oncology is developing a pipeline of targeted oncology candidates based on proprietary immune-cell engagement technologies. These therapies are intended to direct immune cells toward tumor-associated targets and potentially address cancers that are difficult to treat with existing immunotherapies.
The company’s programs remain in development, and publicly available information about its commercial products, geographic operations, and leadership is limited.
See Also
- Five stocks we like better than Aktis Oncology
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
